Evidence map›Paper›PMID 35550441›Full record

ArticleTransplantation and cellular therapy2022

Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.

Betty K Hamilton, Corey Cutler, Clint Divine, Mark Juckett, Charles LeMaistre, Susan Stewart, Jennifer Wilder, Mary Horowitz, Nandita Khera, Linda J Burns

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Betty K HamiltonDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: hamiltb2@ccf.org.
Corey CutlerDivision of Stem Cell Transplantation and Cellular Therapy, Dana Farber Cancer Institute, Boston, Massachusetts.
Clint DivineDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.
Mark JuckettDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Charles LeMaistreSarah Cannon, Nashville, Tennessee.
Susan StewartBlood and Marrow Transplant Information Network, Highland Park, Illinois.
Jennifer WilderClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland.
Mary HorowitzCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Nandita KheraDivision of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, Arizona.
Linda J BurnsCenter for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
BMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumUG1HL069249 · NHLBI · DANA-FARBER CANCER INST · PI Mahasweta Gooptu · 2017 to 2026
$2.2M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069249
6 · The paper itself

Abstract

The need for prospective randomized clinical trials investigating novel graft-versus-host disease (GVHD) prevention strategies that include other clinical outcomes impacted by GVHD has been highlighted as a priority for the field of hematopoietic cell transplantation. A recently completed study through the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1301) comparing CD34

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationClinical Trials as TopicDiterpenesHumansMethotrexateProspective StudiesTacrolimusDiterpenesMethotrexateTacrolimusAllogeneic hematopoietic cell transplantationCD34(+) selectionGraft-versus-host diseasePost-transplantation cyclophosphamide

Identifiers

PMID35550441
PMCPMC9364468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.